SR&ED Credits Accounting Treatment: IFRS vs ASPE Guide for CPAs

The accounting treatment for SR&ED (Scientific Research and Experimental Development) tax credits is one of the most frequently debated topics among Canadian CPAs. With billions of dollars in credits claimed annually, getting the accounting right is not just an academic exercise. It affects reported earnings, tax provisions, balance sheet presentation, and audit outcomes.

The core challenge is that SR&ED credits do not fit neatly into a single accounting standard. Depending on whether the credit is refundable or non-refundable, and whether the entity reports under IFRS or ASPE, the appropriate accounting framework changes entirely. A refundable credit for a Canadian-Controlled Private Corporation (CCPC) behaves like a government grant, while a non-refundable credit for a public company behaves like an income tax credit. Using the wrong standard leads to misstatement, audit adjustments, and potential restatements.

This guide walks through the authoritative accounting treatment under both IFRS and ASPE, with specific journal entries, recognition timing guidance, and practical recommendations for practitioners.

Two Accounting Approaches Under IFRS

Under International Financial Reporting Standards, SR&ED credits can be accounted for under two different standards. The choice depends on the nature of the credit and the reporting entity's circumstances.

IAS 20: Government Grants Approach

IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, applies when the SR&ED credit is refundable and functions as a government grant rather than a reduction in income taxes. This is the standard most commonly applied to CCPC refundable credits at the enhanced 35% rate.

Under IAS 20, the key requirements are:

• Recognition criterion: The grant is recognized when there is "reasonable assurance" that the entity will comply with the conditions attached to the grant and that the grant will be received (IAS 20.7).
• Measurement: The grant is measured at fair value, which for SR&ED credits is the expected cash amount.
• Presentation: IAS 20 permits two presentation approaches:
  • Net approach: The credit is deducted from the related R&D expense in the income statement. This is the most common approach in practice.
  • Gross approach: The credit is presented as "other income" or "government grant income" separately from R&D expense.

The net approach is preferred by most preparers because it reflects the economic substance of the transaction: the government is effectively subsidizing R&D activity, reducing the net cost to the company.

IAS 20 also requires that grants related to expenses be recognized in profit or loss on a systematic basis over the periods in which the entity recognizes as expenses the related costs for which the grants are intended to compensate (IAS 20.12). For SR&ED credits, this means recognizing the credit in the same period as the qualifying R&D expenditures.

IAS 12: Income Taxes Approach

IAS 12, Income Taxes, applies when the SR&ED credit is non-refundable and functions as an investment tax credit that reduces taxes payable. This approach is typical for non-CCPCs claiming at the base 15% rate, where unused credits are carried forward to offset future tax liabilities.

Under IAS 12, the key considerations are:

• Recognition: Non-refundable credits create a temporary difference between the tax base and the carrying amount of the related asset or liability. A deferred tax asset is recognized to the extent it is probable that future taxable profit will be available against which the credit can be utilized (IAS 12.24).
• Measurement: The deferred tax asset is measured at the amount expected to be recovered, based on enacted or substantively enacted tax rates.
• Presentation: The credit flows through income tax expense (either current or deferred), not through operating expenses.

The IAS 12 approach is more conservative for entities with uncertain future profitability, as the recognition of a deferred tax asset requires a "probable" threshold for future taxable income.

Which Approach to Use

The general guidance applied in Canadian practice is:

It is worth noting that IFRS does not explicitly mandate one approach over the other for investment tax credits. IAS 20.2 excludes government assistance provided in the form of "income tax benefits," while IAS 12 does not specifically address government grants. This gap creates a policy choice that must be applied consistently and disclosed in the notes to the financial statements.

ASPE Treatment (Section 3805 and Section 3465)

For private enterprises reporting under Canadian Accounting Standards for Private Enterprises (ASPE), the relevant standards are Section 3805, Government Assistance, and Section 3465, Income Taxes.

Section 3805: Government Assistance

Section 3805 applies to SR&ED credits that are refundable and take the form of government assistance rather than a reduction of income taxes. This is the ASPE equivalent of IAS 20 for grant-like credits.

Key requirements under Section 3805:

• Recognition criterion: Government assistance is recognized when there is "reasonable assurance" that the entity has complied with and will continue to comply with the conditions of the assistance, and that the assistance will be received (Section 3805.05).
• Presentation: The credit is either applied against the related expense (reducing R&D costs) or included in income. The method chosen is a policy election that must be applied consistently (Section 3805.06).
• Repayment provisions: If there is a reasonable possibility that the assistance may need to be repaid (for example, due to clawback provisions), the accounting must reflect this contingency.

In practice, the vast majority of CCPCs using ASPE apply Section 3805 to their refundable SR&ED credits and present the credit as a reduction of R&D expense.

Section 3465: Income Taxes

For non-refundable SR&ED credits under ASPE, Section 3465 governs the accounting treatment. These credits function as investment tax credits (ITCs) that reduce future income taxes payable.

Under Section 3465, non-refundable ITCs are recognized as a reduction of the related expense or asset cost, or as a credit to income, provided that there is reasonable assurance of realization. The assessment of realizability is similar to the IAS 12 "probable" threshold: the entity must have sufficient confidence that future taxable income will be available to absorb the credits before they expire.

Practical Differences from IFRS

While the conceptual framework is similar, there are a few practical differences between ASPE and IFRS treatment of SR&ED credits:

1. Disclosure requirements: IFRS (IAS 20) requires more extensive disclosures, including the nature and extent of government grants recognized, unfulfilled conditions, and contingencies. ASPE disclosures are less prescriptive.
2. Recognition threshold language: IFRS uses "reasonable assurance" (IAS 20) and "probable" (IAS 12), while ASPE uses "reasonable assurance" across both Section 3805 and Section 3465. In practice, the thresholds are interpreted similarly.
3. Presentation flexibility: Under ASPE, there is greater practical flexibility in how credits are presented, as private companies face less regulatory scrutiny on presentation choices.

Refundable vs Non-Refundable Credits

The distinction between refundable and non-refundable SR&ED credits is the single most important factor in determining accounting treatment. Understanding the economic substance of each credit type is essential for correct classification.

Refundable Credits (CCPCs at 35%)

A CCPC or eligible Canadian public corporation (ECPC) with qualifying SR&ED expenditures up to $6 million (the expenditure limit) earns refundable investment tax credits at the enhanced 35% rate. The key features that drive accounting treatment:

• The CRA pays the credit as a cash refund regardless of whether the company has any tax payable.
• The credit is not contingent on the company having taxable income now or in the future.
• The credit functions economically as a government grant or subsidy for R&D activity.
• The claim is filed with the T661 form as part of the corporate tax return.

Because the credit will be received as cash, it meets the definition of government assistance under both IAS 20 and Section 3805. The appropriate accounting treatment is to recognize a receivable when the recognition criteria are met.

Non-Refundable Credits (15% Base Rate)

Non-refundable SR&ED credits at the 15% base rate (applicable to corporations that are neither CCPCs nor ECPCs, and to CCPCs/ECPCs on expenditures above the $6 million threshold) have different economic characteristics:

• The credit only offsets taxes payable. If the company has no tax liability, the credit generates no immediate cash benefit.
• Unused credits can be carried forward 20 years and carried back 3 years.
• The credit functions as a reduction of income tax, not as a government grant.
• Realizability depends on the company's future taxable income projections.

The non-refundable nature of these credits means they are more appropriately accounted for under IAS 12 or Section 3465, as their realization is tied to the income tax system.

Impact on Accounting Treatment Selection

The refundable vs non-refundable distinction creates a clear decision framework:

• If the credit will be received as cash: Treat as a government grant (IAS 20 / Section 3805). Record a receivable and reduce R&D expense or recognize other income.
• If the credit will reduce future taxes: Treat as an income tax credit (IAS 12 / Section 3465). Record a deferred tax asset and reduce income tax expense.
• If the credit is partially refundable: Bifurcate the credit and apply the appropriate standard to each portion.

Journal Entries

The following journal entries illustrate the accounting treatment for common SR&ED credit scenarios. All examples assume the company has incurred $1,000,000 in eligible SR&ED expenditures.

Refundable SR&ED Credit (CCPC, IAS 20 / Section 3805 Approach)

A CCPC claims $350,000 in refundable SR&ED credits (35% x $1,000,000). The company has reasonable assurance the credit will be received based on historical claim success and professional support.

To record the SR&ED credit receivable (net presentation):

Dr  SR&ED Credit Receivable (Balance Sheet)     $350,000
    Cr  R&D Expense (Income Statement)                      $350,000

To record the cash receipt from CRA:

Dr  Cash                                        $350,000
    Cr  SR&ED Credit Receivable                             $350,000

After these entries, the net R&D expense reported on the income statement is $650,000 ($1,000,000 less the $350,000 credit).

If the company elects the gross presentation approach under IAS 20, the credit entry would instead be:

Dr  SR&ED Credit Receivable (Balance Sheet)     $350,000
    Cr  Government Grant Income (Income Statement)          $350,000

Under this approach, R&D expense remains at $1,000,000 and the grant income appears separately.

Non-Refundable SR&ED Credit (IAS 12 / Section 3465 Approach)

A non-CCPC claims $150,000 in non-refundable SR&ED credits (15% x $1,000,000). The company expects to have sufficient taxable income to utilize the credits.

To record the investment tax credit as a deferred tax asset:

Dr  Deferred Tax Asset - ITC (Balance Sheet)    $150,000
    Cr  Income Tax Expense (Income Statement)               $150,000

To apply the credit against taxes payable in a subsequent year:

Dr  Income Tax Payable                          $150,000
    Cr  Deferred Tax Asset - ITC                            $150,000

If the company has current-year tax payable, the credit can be applied immediately:

Dr  Income Tax Payable                          $150,000
    Cr  Income Tax Expense                                  $150,000

Recording a CRA Assessment Adjustment

If the CRA assesses the SR&ED claim at a lower amount than recorded, an adjustment is required. Assume the company initially recorded a $350,000 refundable credit, but the CRA assesses the claim at $280,000 (a $70,000 reduction).

To record the CRA adjustment (net presentation):

Dr  R&D Expense (Income Statement)              $70,000
    Cr  SR&ED Credit Receivable (Balance Sheet)             $70,000

This adjustment is recognized in the period the CRA assessment is received. It is treated as a change in accounting estimate under IAS 8 (IFRS) or Section 1506 (ASPE), not as a correction of a prior period error.

ASPE Equivalents

The journal entries under ASPE are substantively identical to the IFRS entries described above. The difference lies in the authoritative standard referenced (Section 3805 vs IAS 20, Section 3465 vs IAS 12), not in the debits and credits. The presentation choices and recognition criteria are also aligned in practice, though the disclosure requirements differ.

Recognition Timing

One of the most contentious areas in SR&ED credit accounting is the timing of recognition. The core question is: in which fiscal period should the credit be recorded?

Reasonable Assurance (IFRS) vs Reasonable Certainty (ASPE)

Both frameworks require a threshold of confidence before recognition:

• IFRS (IAS 20): "Reasonable assurance" that the conditions will be met and the grant will be received. This is generally interpreted as a high, but not absolute, level of confidence.
• ASPE (Section 3805): The standard also uses "reasonable assurance," aligning the thresholds in practice.

Meeting the recognition threshold requires an assessment of both compliance (have the qualifying conditions been met?) and collectibility (will the CRA actually pay the credit?).

First-Time Claimants vs Experienced Claimants

The recognition timing differs significantly based on the company's history with SR&ED claims:

Experienced claimants (companies with a track record of successful SR&ED claims) can typically recognize the credit in the same period as the qualifying expenditures, even before filing the T661 or receiving a CRA assessment. Their history of successful claims provides reasonable assurance that the current claim will also be received.

First-time claimants face a higher bar. Without historical evidence of CRA acceptance, it may be difficult to demonstrate reasonable assurance. In these cases, a conservative approach is to:

1. Disclose the contingent asset in the notes to the financial statements in the year of expenditure.
2. Recognize the credit only when the CRA assessment is received, or when sufficient professional support (such as a SR&ED consultant's confirmation) provides the required level of assurance.

Impact of CRA Audit History

A company's history of CRA reviews and audit outcomes directly affects recognition timing. Consider these scenarios:

• No prior CRA reviews, consistent full payment: Strong evidence supporting recognition at time of filing.
• Prior CRA review with minor adjustments: Still supportive of recognition at time of filing, but the estimated amount should reflect the expected adjustment rate.
• Prior CRA review with significant adjustments: May require deferring recognition until assessment or recognizing at a reduced "most likely" amount.
• Outstanding CRA dispute or appeal: Portion under dispute should not be recognized until the dispute is resolved.

Common Audit Issues and Pitfalls

External auditors scrutinize SR&ED credit accounting closely. The following are the most common issues encountered during year-end audits.

Premature Recognition

The most frequent audit adjustment relates to recognizing SR&ED credits before the recognition criteria are met. Common examples include:

• Recording the full credit amount before the T661 form has been prepared or reviewed by a qualified consultant.
• Recognizing credits for project activities where the eligibility is uncertain or has not been properly documented.
• First-time claimants recording the credit based solely on management's expectation, without professional support or comparable historical evidence.

Auditors will request evidence of reasonable assurance, including the completed T661, supporting technical documentation, and any professional opinions on claim eligibility.

Inconsistent Treatment Year Over Year

Changing the accounting policy for SR&ED credits between periods (for example, switching from net presentation to gross presentation, or switching between IAS 20 and IAS 12) without proper justification and disclosure is a common pitfall. Any change in policy requires retrospective application and disclosure under IAS 8 (IFRS) or Section 1506 (ASPE).

Failure to Adjust for CRA Assessments

Some companies record SR&ED credits at the filed amount and fail to adjust when the CRA assessment differs. The CRA may reduce claims for several reasons: ineligible expenditures, technical review adjustments, or overhead recalculations. The assessment adjustment must be recognized in the period received.

Provincial Credit vs Federal Credit Presentation

Companies claiming both federal and provincial SR&ED credits (such as the Ontario Innovation Tax Credit, Quebec R&D Tax Credit, or BC BCITC) must account for each credit separately. Each credit has its own refundability rules, rates, and conditions. A common error is aggregating federal and provincial credits into a single line item without considering whether each credit meets its own recognition criteria independently.

Provincial programs have different eligibility criteria and audit processes, so reasonable assurance must be assessed for each credit separately.

Incorrect Classification of Refundable vs Non-Refundable Components

For CCPCs and ECPCs with SR&ED expenditures above the $6 million expenditure limit, the credit has both a refundable component (35% on the first $6M) and a non-refundable component (15% on the excess). Treating the entire credit under a single accounting standard is incorrect. The refundable portion requires IAS 20 / Section 3805 treatment, while the non-refundable portion requires IAS 12 / Section 3465 treatment.

Practical Recommendations for CPAs

Based on common practice and the standards discussed above, the following recommendations will help ensure compliant and defensible SR&ED credit accounting.

1. Establish a consistent accounting policy and document it.
Choose between IAS 20 and IAS 12 (or the ASPE equivalents) based on the nature of the credit. Document the policy election in the company's accounting policy manual and apply it consistently. Disclose the policy in the notes to the financial statements.

2. Bifurcate refundable and non-refundable components.
For CCPCs and ECPCs with expenditures that may exceed the $6 million threshold, calculate each component separately and apply the appropriate standard to each. Do not aggregate the credits for accounting purposes.

3. Assess recognition criteria at each reporting date.
Evaluate reasonable assurance at each balance sheet date. Consider the status of the T661 preparation, the engagement of a qualified SR&ED consultant, the company's historical claim success rate, and any known CRA concerns.

4. Use conservative estimates for first-time claims.
If the company has no SR&ED claim history, consider recognizing only the portion of the credit for which there is strong supporting evidence. Disclose the contingent asset for any unrecognized portion.

5. Reconcile to CRA assessments promptly.
When a Notice of Assessment or Reassessment is received, compare the assessed amount to the recorded receivable and process any adjustments in the current period. Do not restate prior periods unless there is evidence of an error (as opposed to a change in estimate).

6. Maintain audit-ready documentation.
Ensure the T661 claim and supporting technical narratives, project descriptions, and expenditure calculations are completed before recording the credit. Auditors will request this documentation to support the recognition assertion.

7. Consider the impact on financial covenants.
SR&ED credits can materially affect EBITDA, net income, and working capital ratios. If the company has debt covenants that reference these metrics, ensure that the presentation of SR&ED credits is clearly understood by lenders. Discuss the treatment with the lender if the credit is newly recognized or material in amount.

8. Coordinate with SR&ED technical advisors.
The accounting treatment is only as reliable as the underlying claim. Engage qualified SR&ED consultants to prepare the technical portions of the claim and provide a supportable estimate of the expected credit amount. This professional support strengthens the "reasonable assurance" assessment required for recognition.

How to Record an SR&ED Refund: Worked Journal Entries

The entries below use a CCPC with $400,000 of qualifying SR&ED expenditures, a 35% refundable federal credit ($140,000) and a reporting date before the CRA assessment.

If the company presents the credit as other income rather than a reduction of R&D expense, replace the R&D expense credit in row 2 with "Other income (government assistance)" and keep that policy consistent year over year.

Frequently Asked Questions

How do I record an SR&ED refund in the books? When the claim is recognized, debit SR&ED credit receivable and credit R&D expense (or other income) for the expected refundable credit. When the CRA pays, debit cash and credit the receivable. Adjust any difference in the period the Notice of Assessment is received.

What is the journal entry for a refundable SR&ED credit under ASPE? Dr. SR&ED credit receivable / Cr. R&D expense for the refundable 35% credit, in the same period as the qualifying expenditures, once reasonable assurance exists (Section 3805).

What is the journal entry for a non-refundable SR&ED credit under IFRS? Under IAS 12, Dr. deferred tax asset / Cr. income tax expense, only to the extent future taxable profit is probable before the credit expires.

Should SR&ED credits be shown as income or as a reduction of expense? Both are permitted under IAS 20 and ASPE 3805. Pick one presentation, apply it consistently, and disclose it in the notes.

Is an SR&ED refund taxable income? The federal ITC reduces the deductible SR&ED expenditure pool in the following year rather than being added to income directly; provincial credits reduce federal qualified expenditures as government assistance. Confirm with your tax advisor.

When can a first-time claimant recognize the credit? Only when the reasonable-assurance (ASPE/IAS 20) or probable (IAS 12) threshold is met; many preparers recognize the well-supported portion and disclose the rest as a contingent asset until assessment.

Standards and Primary Sources

• IAS 20 Accounting for Government Grants and Disclosure of Government Assistance — IFRS Foundation
• IAS 12 Income Taxes — IFRS Foundation
• ASPE Section 3805 Government Assistance and Section 3465 Income Taxes — CPA Canada Handbook (subscription)
• SR&ED tax incentives — Canada Revenue Agency
• After you claim: CRA review and assessment — Canada Revenue Agency
• Form T661 — Canada Revenue Agency

How to Record an SR&ED Refund: Worked Journal Entries

The entries below use a CCPC with $400,000 of qualifying SR&ED expenditures, a 35% refundable federal credit ($140,000) and a reporting date before the CRA assessment.

If the company presents the credit as other income rather than a reduction of R&D expense, replace the R&D expense credit in row 2 with "Other income (government assistance)" and keep that policy consistent year over year.

Frequently Asked Questions

How do I record an SR&ED refund in the books? When the claim is recognized, debit SR&ED credit receivable and credit R&D expense (or other income) for the expected refundable credit. When the CRA pays, debit cash and credit the receivable. Adjust any difference in the period the Notice of Assessment is received.

What is the journal entry for a refundable SR&ED credit under ASPE? Dr. SR&ED credit receivable / Cr. R&D expense for the refundable 35% credit, in the same period as the qualifying expenditures, once reasonable assurance exists (Section 3805).

What is the journal entry for a non-refundable SR&ED credit under IFRS? Under IAS 12, Dr. deferred tax asset / Cr. income tax expense, only to the extent future taxable profit is probable before the credit expires.

Should SR&ED credits be shown as income or as a reduction of expense? Both are permitted under IAS 20 and ASPE 3805. Pick one presentation, apply it consistently, and disclose it in the notes.

Is an SR&ED refund taxable income? The federal ITC reduces the deductible SR&ED expenditure pool in the following year rather than being added to income directly; provincial credits reduce federal qualified expenditures as government assistance. Confirm with your tax advisor.

When can a first-time claimant recognize the credit? Only when the reasonable-assurance (ASPE/IAS 20) or probable (IAS 12) threshold is met; many preparers recognize the well-supported portion and disclose the rest as a contingent asset until assessment.

Standards and Primary Sources

• IAS 20 Accounting for Government Grants and Disclosure of Government Assistance — IFRS Foundation
• IAS 12 Income Taxes — IFRS Foundation
• ASPE Section 3805 Government Assistance and Section 3465 Income Taxes — CPA Canada Handbook (subscription)
• SR&ED tax incentives — Canada Revenue Agency
• After you claim: CRA review and assessment — Canada Revenue Agency
• Form T661 — Canada Revenue Agency

Conclusion

The accounting treatment for SR&ED credits requires careful analysis of the credit type, the applicable accounting framework, and the specific facts and circumstances of each claim. Refundable credits for CCPCs align with government grant accounting under IAS 20 or ASPE Section 3805, while non-refundable credits align with income tax accounting under IAS 12 or ASPE Section 3465.

The key to getting it right is a well-documented accounting policy, consistent application, timely adjustment for CRA assessments, and strong coordination between the finance team and SR&ED technical advisors. For companies that claim SR&ED credits year over year, this is not a one-time exercise but an ongoing process that should be integrated into the annual close and audit preparation cycle.

If your organization needs help preparing or optimizing your SR&ED claim, GrantOps provides end-to-end support from technical documentation through to filing and audit defense.